Skip to Content

Reports suggesting that CRISPR could cause cancer dinged the stock prices of the big three gene editing companies: Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics all fell by 10 percent or more.

The findings: CRISPR is all about cutting DNA—but cells don’t like that very much. Two papers in the journal Nature Medicine (here and here) found that the damage cause by CRISPR can kill cells or stop them from growing.

The problem: CRISPR is a lot less likely to kill cells with defective versions of a gene called p53, whose anticancer role has led some to call it the guardian of the genome. In short, CRISPR could give a survival advantage to cells likely to turn cancerous, according to Stat.

The upshot: The new findings could help explain why the U.S. Food & Drug Administration placed a planned human study by CRISPR Therapeutics on hold in May. That company has hoped to use CRISPR as a gene therapy to treat sickle-cell disease.

 

Deep Dive

Biotechnology and health

What to know about this autumn’s covid vaccines

New variants will pose a challenge, but early signs suggest the shots will still boost antibody responses.

A biotech company says it put dopamine-making cells into people’s brains

The experiment to treat Parkinson’s is a critical early test of stem cells’ potential to tackle serious disease.

Tiny faux organs could crack the mystery of menstruation

Researchers are using organoids to unlock one of the human body’s most mysterious—and miraculous—processes.

After 25 years of hype, embryonic stem cells are still waiting for their moment

Research roadblocks and political debates have delayed progress—but scientists are inching closer to delivering a cure. 

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.